Galderma Group Ltd Canada (GALD.SW) shared on Monday that Health Canada has given the green light to NEMLUVIO, which is the first biologic treatment specifically for moderate-to-severe atopic dermatitis and prurigo nodularis.
This approval is for patients who are 12 and older dealing with atopic dermatitis, as well as adults with prurigo nodularis who haven't found relief with topical prescriptions.
NEMLUVIO is also notable for being the first monoclonal antibody targeting the IL-31 receptor alpha approved in Canada for these conditions. The endorsement is backed by encouraging phase III trial results from ARCADIA and OLYMPIA, which showed quick and significant improvements in itchiness, skin lesions, and sleep issues.
GALD.SW closed trading on Monday at CHF 163.90 down CHF 1.30 or 0.79 percent on the Six Swiss Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.